Compounds > moxifloxacin
Page last updated: 2024-09-04

moxifloxacin and Critical Illness

moxifloxacin has been researched along with Critical Illness in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Luo, S; Tian, M; Wang, L; Xia, W; Zeng, Y; Zha, Y; Zhang, K; Zhang, X1
Haeberle, HA; Heininger, A; Kees, F; Kees, MG; Kloft, C; Schaeftlein, A1
Boucher, BA; Croce, MA; Fabian, TC; Monteen, MR; Ponnapula, S; Swanson, JM; Wood, GC1
Boussery, K; Colpaert, K; de Paepe, P; de Smet, J; Decruyenaere, J; van Bocxlaer, J1
Czock, D; de Groot, K; Fliser, D; Hafer, C; Haller, H; Hüsig-Linde, C; Keller, F; Kielstein, JT; Kuse, E; Langhoff, A; Schöpke, T; Swoboda, S1

Other Studies

5 other study(ies) available for moxifloxacin and Critical Illness

ArticleYear
The combined therapy of a traditional Chinese medicine formula and Western medicine for a critically ill case infected with COVID-19.
    Complementary therapies in medicine, 2020, Volume: 52

    Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Illness; Drug Combinations; Drugs, Chinese Herbal; Female; Humans; Indoles; Lopinavir; Medicine, Chinese Traditional; Methylprednisolone; Middle Aged; Moxifloxacin; Noninvasive Ventilation; Oxygen Inhalation Therapy; Pandemics; Pneumonia, Viral; Qi; Ritonavir; SARS-CoV-2

2020
Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients.
    The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:6

    Topics: Adolescent; Adult; Aged; Algorithms; Anti-Bacterial Agents; APACHE; Area Under Curve; Aza Compounds; Biological Availability; Chromatography, High Pressure Liquid; Cohort Studies; Computer Simulation; Critical Care; Critical Illness; Enteral Nutrition; Female; Fluorometry; Fluoroquinolones; Humans; Infusions, Intravenous; Intensive Care Units; Male; Middle Aged; Moxifloxacin; Population; Quinolines; Respiration, Artificial; Young Adult

2013
Treatment of Chryseobacterium indologenes ventilator-associated pneumonia in a critically ill trauma patient.
    The Annals of pharmacotherapy, 2013, Volume: 47, Issue:12

    Topics: Aged; Anti-Bacterial Agents; Aza Compounds; Cefepime; Cephalosporins; Chryseobacterium; Critical Illness; Flavobacteriaceae Infections; Fluoroquinolones; Humans; Intensive Care Units; Male; Moxifloxacin; Pneumonia, Ventilator-Associated; Quinolines; Radiography; Wounds and Injuries

2013
Switch from intravenous to enteral moxifloxacin in critically ill patients: a pilot study.
    Scandinavian journal of infectious diseases, 2012, Volume: 44, Issue:11

    Topics: Administration, Intravenous; Administration, Oral; Adult; Anti-Infective Agents; Area Under Curve; Aza Compounds; Biological Availability; Creatine; Critical Illness; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pilot Projects; Pneumonia; Prospective Studies; Quinolines; Therapeutic Equivalency

2012
Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis.
    Clinical journal of the American Society of Nephrology : CJASN, 2006, Volume: 1, Issue:6

    Topics: Acute Kidney Injury; Adult; Aged; Anti-Bacterial Agents; Anuria; Aza Compounds; Critical Care; Critical Illness; Female; Fluoroquinolones; Humans; Intensive Care Units; Levofloxacin; Male; Metabolic Clearance Rate; Middle Aged; Moxifloxacin; Multiple Organ Failure; Ofloxacin; Quinolines; Renal Dialysis; Sepsis

2006